免疫原性
人源化抗体
重组DNA
异源的
抗体
单克隆抗体
中和抗体
计算生物学
抗原
蜘蛛
蛋白质工程
体内
生物
化学
生物化学
免疫学
生物技术
基因
酶
动物
作者
Isabella Gizzi Jiacomini,Martina Beltramino,Fanny Boursin,João Carlos Minozzo,Juliana Ferreira de Moura,Philippe Billiald,Larissa M. Alvarenga,Nicolas Aubrey
标识
DOI:10.1016/j.ijbiomac.2022.06.195
摘要
The use of monoclonal antibodies (mAbs) in therapy is gradually advancing and discussions entail its safety, rentability and effectiveness. To this date, around a hundred mAbs have been approved by the FDA for the treatment of various diseases. Aiming for their large-scale production, recombinant DNA technology is mainly employed, and antibodies can be expressed in various eukaryotic and prokaryotic systems. Moreover, considering their heterologous origin and potential immunogenicity, various strategies have been developed for mAb humanization, considering that around 50 % of commercial mAbs are humanized. Hence, we introduce LimAb7, a mouse mAb capable of binding and neutralizing brown spider's Loxosceles intermedia dermonecrotic toxins in vivo/in vitro. This antibody has been produced in mouse and humanized scFv and diabody formats, however results indicated losses in antigen-binding affinity, stability, and neutralizing ability. Intending to develop evolved, stable, and neutralizing antibody fragments, we report for the first time the design of humanized antibody V-domains produced as Fab fragments, against spider venom toxins. Improvements in constructs were observed regarding their physicochemical stability, target binding and binding pattern maintenance. As their neutralizing features remain to be characterized, we believe this data sheds new light on antibody humanization by producing a parental molecule in different recombinant formats.
科研通智能强力驱动
Strongly Powered by AbleSci AI